Three biologics are approved by the U.S. Food and Drug Administration for the treatment of multiple inflammatory diseases: Canakinumab, a human anti-IL-1β monoclonal antibody, has significant antitumor effects in NSCLC (172, 173); Rilonacept, a decoy receptor that binds IL-1β and IL-1α (176); Anakinra is a recombinant IL-1 receptor antagonist (IL-1RA) that blocks IL-1α and IL-1β signaling via IL-1R (174). This evidence concerns the gene IL1A and non-small cell lung carcinoma.